Schering AG Release: YAZ(R) U.S. Launch Activities Continue As Planned

BERLIN, Germany, March 28 /PRNewswire-FirstCall/ -- Schering AG, Germany confirmed today that it is continuing the launch of its new oral contraceptive YAZ(R) in the U.S.

Today, Schering learned through media reports that Warner Chilcott PLC purportedly filed a suit in the U.S. alleging that Schering is infringing on one of their patents in connection with the marketing of YAZ(R). Schering affirmed that YAZ(R) does not infringe any U.S. patent.

YAZ(R) was recently approved by the U.S. Food and Drug Administration (FDA) as a low dose, monophasic oral contraceptive (3mg drospirenone/20 mcg ethinyl estradiol). It is the first pill with the innovative progestin drospirenone, and a low dose of ethinyl estradiol in a new dosing regimen of 24 days of active hormone pills and four days of placebo.

Schering AG is a research-based pharmaceutical company. Its activities are focused on four business areas: Gynecology&Andrology, Oncology, Diagnostic Imaging as well as Specialized Therapeutics for disabling diseases. As a global player with innovative products Schering AG aims for leading positions in specialized markets worldwide. With in-house R&D and supported by an excellent global network of external partners, Schering AG is securing a promising product pipeline. Using new ideas, Schering AG aims to make a recognized contribution to medical progress and strives to improve the quality of life: making medicine work.

This press release has been published by Corporate Communication of Schering AG, Berlin, Germany.

Your contacts at Corporate Communication:

Media Relations: Oliver Renner , T: +49-30-468-124-31, oliver.renner@schering.de

Pharma Communication: Astrid Kranz, T: +49-30-468-120-57, astrid.kranz@schering.de

Investor Relations: Peter Vogt, T: +49-30-468 128 38, peter.vogt@schering.de

Your contacts in the US:

Media Relations: Kim Schillace Wix, T: +1-973-305-5258, kimberly_schillace@berlex.com

Investor Relations: Joanne Marion, T: +1-973-487-2164, joanne_marion@berlex.com

Find additional information at: www.schering.de/eng

Certain statements in this press release that are neither reported financial results nor other historical information are forward-looking statements, including but not limited to, statements that are predictions of or indicate future events, trends, plans or objectives. Undue reliance should not be placed on such statements because, by their nature, they are subject to known and unknown risks and uncertainties and can be affected by other factors that could cause actual results and Schering AG's plans and objectives to differ materially from those expressed or implied in the forward-looking statements. Certain factors that may cause such differences are discussed in our Form 20-F and Form 6-K reports filed with the U.S. Securities and Exchange Commission. Schering AG undertakes no obligation to update publicly or revise any of these forward-looking statements, whether to reflect new information or future events or circumstances or otherwise.

CONTACT: Your contacts at Corporate Communication: Media Relations: OliverRenner , T: +49-30-468-124 31, oliver.renner@schering.de. PharmaCommunication: Astrid Kranz, T: +49-30-468-120-57,astrid.kranz@schering.de, Investor Relations: Peter Vogt, T:+49-30-468-128-38, peter.vogt@schering.de. Your contacts in the US: MediaRelations: Kim Schillace Wix, T: +1-973-305-5258,kimberly_schillace@berlex.com. Investor Relations: Joanne Marion, T:+1-973-487-2164, joanne_marion@berlex.com